1. Ariyo A.A., Haan M., Tangen C.M. et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Colloborative Research Group // Circulation. – 2000. – Vol. 102, № 15. – Р. 1773-1779.
2. Kawachi I., Colditz G.A. Prospective study of phobic anxiety and risk of coronary heart disease in men // Circulation. – 1994. – Vol. 89, № 5. – P. 1992-1997.
3. Ellis J., Eagle K., Kline-Rogers E., Erickson S.R. Depressive symptoms and treatment after acute coronary syndrome // Int. J. Cardiol. – 2005. – Vol. 99, № 33. – P. 443-447.
4. Hamilton M. Hamilton anxiety scale // In: Gue W. ed. ECDEU Assessment manual for psycholopharmacology. Rev. Ed. - Washington DC: US Department of Health, Education and Welfare, 1976. – P. 193-198.
5. Hamilton M. A rating for depression // J. Neurol. Neurosurg. Psych. – 1960. – Vol. 23. – P. 56-61.
6. Efron B. Forcing a sequential experiment to be balanced // Biometrica. – 1971. – Vol. 58. – P. 403-417.
7. Ressler K.J., Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders // Depress. Anxiety. – 2000. – Vol. 12, suppl. 1. – P. 2-19.
8. Brewerton T.D., Lydiard M.R., Johnson M.R. et all. CSF Serotonin: diagnostic and seasonal differences, Abstract № 358 // In: New research and abstracts of the 148th Annual Meeting of the American Psychiatric Association; May 20-25, 1995. - Miami, Fla., 1995. – P. 151.
9. Iny L.J., Pecknold J., Suranyi-Cadotte B.E. et all. Studies of a nerochemical link between depression, anxiety and stress fromimipramine andparoxetine binding n human platelets // Biol. Psychiatry. – 1994. – Vol. 36, № 5. – P. 281-291.
10. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine // Prog. Neurobiol. – 2001. – Vol. 63, № 6. – Р. 637-672.
11. Millan M.J. The neurobiology and control of anxious states // Prog. Neurobiol. – 2003. – Vol. 70, № 2. – Р. 83-244.
12. Nelson J.C., Kennedy J.S., Pollock B.G. et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease // Am. J. Psychiatry. – 1999. – Vol. 156, № 7. – P. 1024-1028.
13. Rocca P., Fonzo V., Scotta M. et al. Paroxetine efficacy in the treatment of generalized anxiety disorders // Acta Psychiatr. Scand. – 1997. – Vol. 95, № 5. – Р. 444-450.
14. Regan K.L. Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review // J. Cardiovasc. Nurs. – 2008. – Vol. 23, № 6. – Р. 489-496.
15. Llorca P.M., Spadone C., Sol O. et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study // J. Clin. Psychiatry. – 2002. – Vol. 63, № 11. – Р. 1020-1027.
16. Figueras G., Pérez V., San Martino O. et al. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos // Biol. Psychiatry. – 1999. – Vol. 46, № 4. – Р. 518-524.
17. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies // J. Clin. Psychiatry. – 2001. – Vol. 62, suppl. 12. – P. 16-23.